- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02772159
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
A Single-Dose, Fixed-Sequence, Two-Period Study to Evaluate the Absorption, Distribution, Metabolism, Excretion of TD-4208 Following an IV Infusion and an Oral Dose of [14C]-Labeled TD-4208 in Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, fixed-sequence, two-period study in up to 12 healthy male subjects. The present study is designed to fully characterize the rates and routes of elimination of TD 4208 using radiolabeled drug administered via the oral and IV route. This study will provide information regarding the metabolic fate of TD 4208, the need for evaluation of potential drug-drug interactions, the need for studies in special populations and the absolute oral bioavailability of TD-4208. The results from this study will allow a comprehensive comparison between animal and human routes of elimination and metabolic profiles of TD 4208.
This study will be conducted in a small number of healthy male subjects (up to n=12) to minimize the number of individuals exposed to radioactivity. Each subject will receive the following treatments: Treatment A (Period 1): 20 μg IV infusion of [14C] TD-4208 administered in a fasted state over 30 minutes. Treatment B (Period 2): 200 μg oral solution of [14C] TD-4208 administered in a fasted state. Blood, urine, feces, and vomitus (if applicable) will be collected until the subject is released during Periods 1 and 2. In Periods 1 and 2, subjects may remain in the clinical research unit for a maximum of 15 days. Between the dosing in periods 1 and 2, there will be washout intervals of at least 28 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has a body mass index 19 to 32 kg/m2, inclusive, and weigh at least 55 kg.
- Subject has normal blood pressure (BP) and heart rate (HR), measured after resting seated or supine for approximately 5 minutes. Normal BP is defined as 90 to 140 mm Hg systolic and 50 to 90 mm Hg diastolic. Normal HR is defined as 40 to 99 beats per minute.
- Subject is negative for hepatitis B, hepatitis C, and HIV antibodies.
- Subject has no clinically relevant abnormalities as determined by the investigator in the results of Screening or Day -1 laboratory evaluations.
Exclusion Criteria:
- Subject has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]).
- Subject has participated in another clinical trial of an investigational drug (or medical device) within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to Screening, or are currently participating in another trial of an investigational drug (or medical device).
- Subject has a known hypersensitivity towards medications similar to TD-4208 or excipients contained in TD-4208.
- Subject has previously participated in a trial for TD-4208.
- Subject regularly works with ionizing radiation or radioactive material.
- Subject has been exposed to ionizing radiations, within 1 year prior to the start of the study, as external irradiation (radiological examination including CT scan excluding dental radiography) or internal radiation (diagnostic nuclear medicine procedure) or have participated in a radiolabeled study in the last 12 months.
- Subject has had exposure to external and/or internal radiotherapy with open (i.e., nuclear medicine) and sealed sources (i.e., brachytherapy) within the last 12 months.
- Subject, who, for any reason, is deemed by the investigator to be inappropriate for this study or have any condition which would confound or interfere with the evaluation of the safety, tolerability, PK of the investigational drug or prevent compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Population
One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes.
B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
|
One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes.
B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
[14C] total radioactivity in urine and reported as the recovery in urine as a percentage of the administered dose
Time Frame: up to 336 hours
|
up to 336 hours
|
[14C] total radioactivity in feces and reported as the recovery in feces as a percentage of the administered dose
Time Frame: up to 336 hours
|
up to 336 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Whole blood concentrations of total radioactivity
Time Frame: up to 336 hours
|
up to 336 hours
|
Plasma concentrations of total radioactivity
Time Frame: up to 336 hours
|
up to 336 hours
|
Plasma concentrations of TD-4208
Time Frame: up to 336 hours
|
up to 336 hours
|
Plasma concentrations of THRX-195518
Time Frame: up to 336 hours
|
up to 336 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Medical Monitor, Theravance Biopharma, US, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0130
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
Clinical Trials on TD-4208
-
Mylan Inc.Theravance BiopharmaCompleted
-
Mylan Inc.Theravance BiopharmaCompleted
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
Mylan Inc.Theravance BiopharmaCompleted
-
Mylan Inc.Theravance BiopharmaCompletedHepatic ImpairmentUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States
-
Mylan Inc.Theravance BiopharmaCompletedCardiac Repolarization in Healthy SubjectsUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease, COPDNew Zealand
-
Theravance BiopharmaCompletedInflammatory Bowel Diseases | IBDUnited States